Venetoclax plus cytarabine and azacitidine in relapsed/refractory AML: An open-label, single-arm, phase 2 study.
You L, Liu Y, Mai W, Xie W, Zhou D, Mao L, Chen L, Zhou X, Ma L, Zheng X, Wei J, Lou Y, Ye X, Tong H, Jin J, Meng H.
You L, et al. Among authors: tong h.
Eur J Cancer. 2024 May;202:113979. doi: 10.1016/j.ejca.2024.113979. Epub 2024 Mar 1.
Eur J Cancer. 2024.
PMID: 38471289
Clinical Trial.